Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes
US-12173314-B2 · Dec 24, 2024 · US
Method of inducing expression of calcium channel and/or calcium pump, and apparatus therefor
US12590291B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12590291-B2 |
| Application number | US-202217729752-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 26, 2022 |
| Priority date | Apr 27, 2021 |
| Publication date | Mar 31, 2026 |
| Grant date | Mar 31, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method of inducing expression of a calcium channel and/or a calcium pump in a cell includes: irradiating the cell with light in a wavelength range of 315-325 nm. The calcium channel and/or the calcium pump is/are at least one selected from the group consisting of dihydropyridine receptor (DHPR), voltage-gated calcium channel (VGCC), ryanodine receptor (RYR), and sarcoendoplasmic reticulum Ca 2+ -ATPase (SERCA).
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of inducing gene expression of a calcium channel and/or a calcium pump in a cell, the method comprising: irradiating the cell with light in a wavelength range of 315-325 nm, wherein the calcium channel and/or the calcium pump is/are at least one selected from the group consisting of dihydropyridine receptor (DHPR), voltage-gated calcium channel (VGCC), ryanodine receptor (RYR), and sarcoendoplasmic reticulum Ca 2+ -ATPase (SERCA). 2 . The method according to claim 1 , wherein in the step of irradiating, the cell is not irradiated with light at any wavelength of 330-400 nm, or is irradiated with light in wavelengths of 330-400 nm at a fluence that is less than 50% of that of the light in the wavelength range of 315-325 nm. 3 . The method according to claim 1 , wherein in the step of irradiating, the cell is not irradiated with light at any wavelength of 200-300 nm, or is irradiated with light in wavelengths of 200-300 nm at a fluence that is less than 30% of that of the light in the wavelength range of 315-325 nm. 4 . The method according to claim 1 , wherein the light in the wavelength range of 315-325 nm has a wavelength spectrum with a peak wavelength at 320±5 nm and a full width at half maximum in a range of 1-20 nm. 5 . The method according to claim 1 , wherein the light in the wavelength range of 315-325 nm is emitted by a light-emitting diode (LED). 6 . The method according to claim 1 , wherein the cell is an excitatory cell. 7 . A method of modulating calcium signaling in a cell, the method comprising: inducing gene expression of a calcium channel and/or a calcium pump in the cell by applying the method according to claim 1 to the cell; and measuring a physiological event involving calcium signaling in the cell. 8 . The method according to claim 7 , wherein the physiological event is one or more selected from the group consisting of muscle contraction, neuronal transmission, cell death, and osteoblast-like differentiation. 9 . A method of making a cell having induced gene expression of a calcium channel and/or a calcium pump, comprising: irradiating a cell with light in a wavelength range of 315-325 nm; and freezing the irradiated cell, wherein, in the step of irradiating: the cell is not irradiated with light at any wavelength of 200-300 nm, or is irradiated with light in wavelengths of 200-300 nm at a fluence that is less than 30% of that of the light in the wavelength range of 315-325 nm, and the cell is not irradiated with light at any wavelength of 330-400 nm, or is irradiated with light in wavelengths of 330-400 nm at a fluence that is less than 50% of that of the light in the wavelength range of 315-325 nm. 10 . The method of claim 1 , wherein the light in the wavelength range of 315-325 nm has a fluence of 50-4,500 mJ/cm 2 .
Assignees
Inventors
Classifications
Multiple separable units; Modules · CPC title
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title
Petri dish (crystallising dishes B01L3/06) · CPC title
Quantitative amplification · CPC title
Photobioreactors (culturing algae A01G33/00, A01H4/001, C12N1/12) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12590291B2 cover?
- A method of inducing expression of a calcium channel and/or a calcium pump in a cell includes: irradiating the cell with light in a wavelength range of 315-325 nm. The calcium channel and/or the calcium pump is/are at least one selected from the group consisting of dihydropyridine receptor (DHPR), voltage-gated calcium channel (VGCC), ryanodine receptor (RYR), and sarcoendoplasmic reticulum Ca …
- Who is the assignee on this patent?
- Nichia Corp
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0629. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).